The News Review:
- Firm enters world of drug trials
- vercoming virus early beats hepatitis
- Press Release Distribution from 24-7PressRelease.com
Firm enters world of drug trials
Milwaukee Journal Sentinel – Milwaukee Journal Sentinel (subscription… – May 24, 2008
Add to the mix allegations against one Florida center of coercing immigrants into staying in studies and some high-profile instances in which volunteers got very ill or died. It’s a system that Robert Helms a former guinea pig who’s now an advocate for human research subjects calls a “total mess. ” And it’s one that Spaulding Clinical Research LLC wants to change. The company bought the 200000-square-foot former St. Joseph’s Community Hospital building last month from SynergyHealth after it moved three miles down the road. Spaulding Clinical will lease about one-third of the space to SynergyHealth for its business offices and cancer center. In the rest it will run clinical trials and house medical equipment like high-density cardiac scanners and ultrasound machines which will help it achieve higher quality testing said Randy Spaulding the company’s founder and CE.
vercoming virus early beats hepatitis
The Australian – May 24, 2008
All the participants who achieved RVR went on to achieve SVR and even 59 per cent of those who did not achieve RVR went on to be cured later. The study’s authors concluded that patients treated for acute hepatitis C infection and who achieved RVR "are highly likely to achieve SVR irrespective of HIV status". "This is the largest study ever of an injecting drug-user population with early infection" said professor Dore who is head of the viral hepatitis clinical research program at the Sydney-based National Centre in HIV Epidemiology and Clinical Research. "We have shown that it is feasible to treat this group many of whom have been recent injecting drug users and get remarkably good outcomes. "What we are looking at now is to apply to the NIH for another five years’ funding to look at the different strategies to optimise treatment outcomes in this group. " Dore’s colleague doctor Gail Matthews said the high proportion of HIV-positive cases in the study participants about one-third "probably reflects a current increase in acute HCV in this population – predominantly acquired through sexual transmission and mirroring what is being reported from many centres in Europe". "This has potential implications for public health messages in this group" she said.
Press Release Distribution from 24-7PressRelease.com
24-7PressRelease.com – 24-7PressRelease.com (press release) – May 24, 2008
pr_image { padding:2px; border: solid 1px #eeeeee;}–>. The acquisition of B & I with over 20 years of oncology CR experience significantly compliments Veeda ncologys capability within mainland Europe. Announcing the acquisition Mr. Binoy Gardi Co-Managing Director of the Veeda Group said the acquisition of B & I is one significant pillar that we are adding to our global oncology presence within the oncology CR marketplace.
